Pivotal bioVenture Partners Investment Advisor LLC reported 13 positions worth $307.79M for the quarter ended Jun 30, 2026, up 10.0% on the prior quarter. It opened 1 new position, added to 3, trimmed 4 and exited 1. Its largest holding is Vaxcyte, Inc. at 26.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ZBIO Zenas BioPharma, Inc. | -101.2K | -17.1% | $2.57M | 4.05% |
| OCS Oculis Holding AG | -174.0K | -10.4% | $2.41M | 6.79% |
| ARQT Arcutis Biotherapeutics, Inc. | -90.6K | -6.7% | $2.38M | 10.78% |
| BOLT Bolt Biotherapeutics, Inc. | -42.6K | -100.0% | $172.03K | Exited |
| MPLT MapLight Therapeutics, Inc. | -1 | 0.0% | $35.84 | 7.12% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| AVLN Avalyn Pharma Inc. | +966.8K | $31.83M | 10.34% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| BOLT Bolt Biotherapeutics, Inc. | -42.6K | $172.03K | 0.061% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | PCVX Vaxcyte, Inc. | Healthcare | 1.43M | $82.86M | 26.92% | +53.0K | +3.9% | Added | 0.98% |
| 2 | ARQT Arcutis Biotherapeutics, Inc. | Healthcare | 1.27M | $33.18M | 10.78% | -90.6K | -6.7% | Reduced | 0.97% |
| 3 | TRVI Trevi Therapeutics, Inc. | Healthcare | 1.74M | $32.50M | 10.56% | +188.9K | +12.2% | Added | 1.11% |
| 4 | AVLN Avalyn Pharma Inc. | Healthcare | 966.8K | $31.83M | 10.34% | +966.8K | – | New | 2.18% |
| 5 | EVMN Evommune, Inc. | Healthcare | 1.93M | $25.61M | 8.32% | 0 | 0.0% | Unchanged | 5.31% |
| 6 | MPLT MapLight Therapeutics, Inc. | Healthcare | 611.4K | $21.91M | 7.12% | -1 | 0.0% | Reduced | 1.35% |
| 7 | OCS Oculis Holding AG | Healthcare | 1.51M | $20.89M | 6.79% | -174.0K | -10.4% | Reduced | 2.88% |
| 8 | BIOA BioAge Labs, Inc. | Healthcare | 653.4K | $16.01M | 5.2% | 0 | 0.0% | Unchanged | 1.43% |
| 9 | IMNM Immunome Inc. | Healthcare | 732.5K | $15.52M | 5.04% | 0 | 0.0% | Unchanged | 0.65% |
| 10 | ZBIO Zenas BioPharma, Inc. | Healthcare | 490.8K | $12.46M | 4.05% | -101.2K | -17.1% | Reduced | 0.77% |
| 11 | AVTX Avalo Therapeutics, Inc. | Healthcare | 434.0K | $8.02M | 2.61% | +138.1K | +46.7% | Added | 0.82% |
| 12 | RLYB Rallybio Corp | Healthcare | 300.6K | $4.81M | 1.56% | 0 | 0.0% | Unchanged | 5.27% |
| 13 | RXRX Recursion Pharmaceuticals, Inc. | Healthcare | 595.5K | $2.19M | 0.71% | 0 | 0.0% | Unchanged | 0.11% |
Tip. Select a row to see that position’s full history at Pivotal bioVenture Partners Investment Advisor.
As of its Q2 2026 13F filing, Pivotal bioVenture Partners Investment Advisor LLC’s five largest positions were Vaxcyte, Inc. (PCVX) at 26.9%, Arcutis Biotherapeutics, Inc. (ARQT) at 10.8%, Trevi Therapeutics, Inc. (TRVI) at 10.6%, Avalyn Pharma Inc. (AVLN) at 10.3%, Evommune, Inc. (EVMN) at 8.3% of the reported portfolio.
Pivotal bioVenture Partners Investment Advisor LLC reported a 13F portfolio worth $307.79M across 13 positions for Q2 2026. That is up 10.0% from the previous quarter.
Its largest purchases by value were Avalyn Pharma Inc. ($31.83M), Trevi Therapeutics, Inc. ($3.52M), Vaxcyte, Inc. ($3.08M). It opened 1 new positions.
Its largest sales by value were Zenas BioPharma, Inc. ($2.57M), Oculis Holding AG ($2.41M), Arcutis Biotherapeutics, Inc. ($2.38M). It exited 1 positions entirely.
From the Form 13F-HR reports Pivotal bioVenture Partners Investment Advisor LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.